argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026

argenx SE will present new data from its Phase 3 study of VYVGART Hytrulo, an FcRn blocker, focusing on autoimmune myositis, specifically IMNM and DM, at the ACR Convergence 2026. Results from the ALKIVIA study indicate that efgartigimod provides significant patient improvements as early as Week 4, sustained through 52 weeks. The late-breaking presentation is scheduled for November 11, 2026, in Orlando, Florida.